US 12,109,230 B2
Treatment of neurodegenerative disease with sodium chlorite
Vernon A. Norviel, San Diego, CA (US); and Michael S. McGrath, Meadow Vista, CA (US)
Assigned to NEUVIVO, INC., Palo Alto, CA (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by Neuvivo, Inc., Palo Alto, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 14, 2024, as Appl. No. 18/441,611.
Application 18/441,611 is a continuation of application No. 18/095,202, filed on Jan. 10, 2023, granted, now 11,938,149.
Application 18/095,202 is a continuation of application No. 17/823,489, filed on Aug. 30, 2022, granted, now 11,938,147.
Application 17/823,489 is a continuation of application No. 15/772,317, abandoned, previously published as PCT/US2016/059915, filed on Nov. 1, 2016.
Claims priority of provisional application 62/249,846, filed on Nov. 2, 2015.
Prior Publication US 2024/0261325 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/20 (2006.01); A61P 25/28 (2006.01)
CPC A61K 33/20 (2013.01) [A61P 25/28 (2018.01)] 20 Claims
 
1. A method of treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof, the method comprising:
a) determining that the subject has a plasma level of C-reactive protein that is at least 1125 ng/ml; and
b) based on the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL, administering to the subject an amount of sodium chlorite that is therapeutically-effective for Amyotrophic Lateral Sclerosis (ALS),
wherein the subject is human;
wherein the subject exhibits a symptom of Amyotrophic Lateral Sclerosis (ALS);
wherein the sodium chlorite is administered in an amount ranging from 0.1 to 10 mg/kg by body weight of the subject;
wherein the administering occurs at least once per month for a period of at least a year; and
wherein the administering occurs over a period ranging from about 0.5 to about 4 hours.